| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
|
Blood
|
2004
|
3.84
|
|
2
|
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.
|
Blood
|
2008
|
2.76
|
|
3
|
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.
|
Blood
|
2005
|
2.44
|
|
4
|
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
|
Clin Cancer Res
|
2006
|
2.44
|
|
5
|
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
|
Blood
|
2006
|
2.18
|
|
6
|
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
|
J Clin Oncol
|
2009
|
2.16
|
|
7
|
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.
|
Neuro Oncol
|
2007
|
1.84
|
|
8
|
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
|
Blood
|
2005
|
1.83
|
|
9
|
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
|
J Clin Oncol
|
2008
|
1.69
|
|
10
|
Improved renal ischemia tolerance in females influences kidney transplantation outcomes.
|
J Clin Invest
|
2016
|
1.51
|
|
11
|
Essential and unique roles of PIP5K-gamma and -alpha in Fcgamma receptor-mediated phagocytosis.
|
J Cell Biol
|
2009
|
1.23
|
|
12
|
Phospholipase cbeta is critical for T cell chemotaxis.
|
J Immunol
|
2007
|
1.22
|
|
13
|
The relative role of PLCbeta and PI3Kgamma in platelet activation.
|
Blood
|
2005
|
1.09
|
|
14
|
A novel testis ubiquitin-binding protein gene arose by exon shuffling in hominoids.
|
Genome Res
|
2007
|
1.07
|
|
15
|
Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis.
|
Blood
|
2009
|
0.96
|
|
16
|
Small interfering RNA-directed knockdown of S100A4 decreases proliferation and invasiveness of osteosarcoma cells.
|
Cancer Lett
|
2010
|
0.92
|
|
17
|
Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
|
Clin Pharmacokinet
|
2003
|
0.92
|
|
18
|
In situ axially doped n-channel silicon nanowire field-effect transistors.
|
Nano Lett
|
2008
|
0.92
|
|
19
|
A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects.
|
Clin Pharmacokinet
|
2008
|
0.92
|
|
20
|
Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
|
Clin Pharmacol Ther
|
2005
|
0.92
|
|
21
|
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.
|
Haematologica
|
2012
|
0.89
|
|
22
|
Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study.
|
Eur J Endocrinol
|
2012
|
0.88
|
|
23
|
Absorption of rivastigmine from different regions of the gastrointestinal tract in humans.
|
J Clin Pharmacol
|
2004
|
0.88
|
|
24
|
A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers.
|
Drug Des Devel Ther
|
2012
|
0.87
|
|
25
|
Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.
|
J Clin Pharmacol
|
2011
|
0.86
|
|
26
|
Meclizine metabolism and pharmacokinetics: formulation on its absorption.
|
J Clin Pharmacol
|
2011
|
0.86
|
|
27
|
Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.
|
Eur J Clin Pharmacol
|
2014
|
0.86
|
|
28
|
Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers.
|
Cancer Chemother Pharmacol
|
2012
|
0.85
|
|
29
|
Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia.
|
Br J Clin Pharmacol
|
2011
|
0.83
|
|
30
|
Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
|
Cancer Chemother Pharmacol
|
2012
|
0.83
|
|
31
|
Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.
|
Cancer Chemother Pharmacol
|
2013
|
0.82
|
|
32
|
Silicidation of silicon nanowires by platinum.
|
Nano Lett
|
2007
|
0.81
|
|
33
|
High-resolution frequency measurement method with a wide-frequency range based on a quantized phase step law.
|
IEEE Trans Ultrason Ferroelectr Freq Control
|
2013
|
0.81
|
|
34
|
An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels.
|
Am J Ther
|
2014
|
0.80
|
|
35
|
Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients.
|
Curr Clin Pharmacol
|
2008
|
0.79
|
|
36
|
PI3K regulates pleckstrin-2 in T-cell cytoskeletal reorganization.
|
Blood
|
2006
|
0.78
|
|
37
|
Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.
|
Endocrine
|
2012
|
0.78
|
|
38
|
Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial.
|
Mol Cancer Ther
|
2011
|
0.78
|
|
39
|
Kinetics of pulmonary immune cells, antibody responses and their correlations with the viral clearance of influenza A fatal infection in mice.
|
Virol J
|
2014
|
0.77
|
|
40
|
Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.
|
J Pharmacol Exp Ther
|
2003
|
0.77
|
|
41
|
Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce.
|
Biopharm Drug Dispos
|
2003
|
0.77
|
|
42
|
Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.
|
Clin Ther
|
2012
|
0.77
|
|
43
|
Bioavailability enhancement of glucosamine hydrochloride by chitosan.
|
Int J Pharm
|
2013
|
0.77
|
|
44
|
Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study.
|
J Clin Pharmacol
|
2012
|
0.76
|
|
45
|
[Expression and clinical significance of CD8+natural killer T cell stimulatory receptor NKG2D in peripheral blood of lung cancer patients].
|
Zhongguo Fei Ai Za Zhi
|
2010
|
0.76
|
|
46
|
Aggregation of wedge-shaped perylenetetracarboxylic diimides with a different number of hydrophobic long alkyl chains.
|
J Colloid Interface Sci
|
2010
|
0.76
|
|
47
|
Application of physiologically based absorption modeling to formulation development of a low solubility, low permeability weak base: mechanistic investigation of food effect.
|
AAPS PharmSciTech
|
2014
|
0.76
|
|
48
|
Recombinant Goat VEGF164 Increases Hair Growth by Painting Process on the Skin of Shaved Mouse.
|
Asian-Australas J Anim Sci
|
2014
|
0.75
|
|
49
|
6-Meth-oxy-meth-oxy-7-trifluoro-methyl-1,3-benzodioxole-5-carbaldehyde.
|
Acta Crystallogr Sect E Struct Rep Online
|
2012
|
0.75
|
|
50
|
Micro-Nanostructured Polyaniline Assembled in Cellulose Matrix via Interfacial Polymerization for Applications in Nerve Regeneration.
|
ACS Appl Mater Interfaces
|
2016
|
0.75
|
|
51
|
Metabolism of patupilone in patients with advanced solid tumor malignancies.
|
Invest New Drugs
|
2012
|
0.75
|
|
52
|
Highly biocompatible nanofibrous microspheres self-assembled from chitin in NaOH/urea aqueous solution as cell carriers.
|
Angew Chem Int Ed Engl
|
2015
|
0.75
|
|
53
|
[Cloning and expression pattern of erk2 gene in Inner Mongolia Cashmere goat].
|
Sheng Wu Gong Cheng Xue Bao
|
2013
|
0.75
|
|
54
|
Detection of DNA damage induced by styrene oxide in dsDNA layer-by-layer films using adriamycin as electroactive probe.
|
Colloids Surf B Biointerfaces
|
2009
|
0.75
|
|
55
|
[Effect of BMSCs transplantation on VEGF receptor fetal liver kinase 1 after spinal cord injury in rats].
|
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
|
2008
|
0.75
|
|
56
|
Application of melt granulation technology using twin-screw extruder in development of high-dose modified-release tablet formulation.
|
J Pharm Sci
|
2010
|
0.75
|
|
57
|
[EFFICACY COMPARISON BETWEEN DEEP MEDIAL COLLATERAL LIGAMENT REPAIR AND CONSERVATIVE TREATMENT FOR COMPLETE MEDIAL COLLATERAL LIGAMENT RUPTURE].
|
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
|
2016
|
0.75
|
|
58
|
Photoinduced electron and energy transfer in dyads of porphyrin dimer and perylene tetracarboxylic diimide.
|
Chemphyschem
|
2008
|
0.75
|
|
59
|
Identification of metabolites of a substance P (neurokinin 1 receptor) antagonist in rat hepatocytes and rat plasma.
|
Drug Metab Dispos
|
2002
|
0.75
|
|
60
|
MECP2 expression in gastric cancer and its correlation with clinical pathological parameters.
|
Medicine (Baltimore)
|
2017
|
0.75
|
|
61
|
Supramolecular self-assembly study of a flexible perylenetetracarboxylic diimide dimer in Langmuir and Langmuir-Blodgett films.
|
J Colloid Interface Sci
|
2008
|
0.75
|
|
62
|
A facile cation exchange-based aqueous synthesis of highly stable and biocompatible Ag₂S quantum dots emitting in the second near-infrared biological window.
|
Dalton Trans
|
2014
|
0.75
|